Initiation And Adherence With Bone-Targeting Agents In Us Men With Bone Metastases From Prostate Cancer

e13083Background: Bone metastases (BM) are common in advanced prostate cancer patients and can lead to serious skeletal-related events (eg, pathological fracture). Two bone-targeting agents (BTAs) are approved in the US for prevention of skeletal-related events in men with BM from prostate cancer – denosumab and zoledronic acid. We sought to provide a current and comprehensive description of BTA use in this population. Methods: Using structured and unstructured data (processed via technology-enabled abstraction) from a large, longitudinal electronic health record database of patients receiving care at oncology practices across the US (Flatiron Health), we identified adult prostate cancer patients with a confirmed diagnosis of BM in 2012/2013 and no evidence of BTA use in the 6 months prior to diagnosis. Patients were followed through 04/30/2015. We estimated the cumulative incidence of BTA initiation after BM diagnosis, treating death as a competing event. Among BTA users, we used multivariable repeated m...